Company Event on Friday, September 4th 2009!

BRAHMS KRYPTOR compact is certified by the Fetal Medicine Foundation (FMF)

Hennigsdorf, Germany, 16-07-2009. The Fetal Medicine Foundation (FMF) confirmed that BRAHMS KRYPTOR compact is fulfilling the requirements for first trimester biochemical screening.

New Cardiac Marker Copeptin accelerates Diagnosis of Acute Myocardial Infarction (AMI)

Hennigsdorf, July 2, 2009. The novel biomarker Copeptin can improve patient management in the Emergency Department (ED). The study “Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction (AMI)” was recently published in the Journal of the American College of Cardiology (JACC).

BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests

Berlin, Germany / Nimes, France / Richmond, CA, U.S.A., June 22, 2009. Diagnostics company BRAHMS Aktiengesellschaft, Cezanne and Lumiphore Inc., a biotechnology leader from California, announced that they have signed an agreement on incorporation of Lumiphore’s Lumi4®-Tb complexes in BRAHMS diagnostic tests.

B·R·A·H·M·S Iberia S.L. starts business operations

B·R·A·H·M·S Aktiengesellschaft is pleased to announce the incorporation of its Spanish affiliate denominated B·R·A·H·M·S Iberia S.L.

For the first time, a new Biomarker test enables early detection of Alzheimer’s dementia in blood.

Hennigsdorf, 15.05.2009. A recent study published in the journal "Biological Psychiatry" substantiates the interrelation between the variations in the microcirculation and the Alzheimer’s disease. With the aid of the new Biomarker tests, these variations can be measured and Alzheimer’s diseases can be diagnosed with greater accuracy. Chances for therapy can be highly improved with early diagnosis of the disease.

Diagnostics company B·R·A·H·M·S presents positive results for 2008

Berlin, 05/13/2009. In contrast to the development of the overall economy, B·R·A·H·M·S Aktiengesellschaft increased its revenue by 19% in 2008. The basis for this success was the recognized test procedures associated with biomarker diagnostics. The PCT sepsis test in particular made a key contribution to the record earnings in 2008.

B·R·A·H·M·S at the annual Heart Failure Congress 2009

B·R·A·H·M·S Aktiengesellschaft will participate in the Heart Failure Congress from 30 May to 2 June 2009 in Palais Acropolis, Nice / France.

Study results on new cardiac marker from B·R·A·H·M·S AG presented at the ACC Congress in Orlando, Florida

Hennigsdorf, April 3, 2009. On March 30, Dr. Tobias Reichlin showed the results of a study, co-initiated by B·R·A·H·M·S in a Late Breaking Clinical Trial Presentation, titled “Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction.”

Second B·R·A·H·M·S Prenatal Screening Forum a massive success

At the invitation of B·R·A·H·M·S Aktiengesellschaft, 111 individuals made their way to Berlin for the March 7, 2009 forum on the most recent developments in prenatal screening. Participants from 26 countries made the forum a truly international event, which offered not only renowned speakers, but also ample time and space for informal exchanges.